December 03, 2020
A New York federal judge ruled Wednesday that a Swiss businessman ignoring civil and criminal cases accusing him of engaging in insider trading ahead of Sanofi SA's acquisition of Bioverativ Inc. owes the U.S. Securities and Exchange Commission $9.8 million, down from the requested $14.8 million.
November 10, 2020
The U.S. Securities and Exchange Commission is seeking $14.8 million from a Swiss businessman who has ignored civil and criminal lawsuits accusing him of engaging in insider trading ahead of Sanofi SA's acquisition of Bioverativ Inc.
June 13, 2019
A Swiss businessman has been charged in the U.S. with insider trading ahead of Sanofi SA's acquisition of Bioverativ Inc. last year in an alleged get-rich-quick scheme that netted cash and stock options worth $4.7 million, prosecutors announced on Thursday.